ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.937,70
-0,21%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Vigil Neuroscience Inc (VIGL)

  7. Vigil Neuroscience Inc (VIGL) News

VIGL

Vigil Neuroscience (VIGL)

Vigil Neuroscience Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VIGL
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202413h40GlobeNewswire Inc.Vigil Neuroscience to Present at The Citizens JMP Life Sciences ConferenceNASDAQ:VIGLVigil Neuroscience Inc
07/05/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/05/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/05/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/05/202423h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
07/05/202422h35Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
07/05/202422h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
07/05/202422h05GlobeNewswire Inc.Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
17/04/202422h05GlobeNewswire Inc.Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
26/03/202412h05GlobeNewswire Inc.Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
20/03/202412h05GlobeNewswire Inc.Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical OfficerNASDAQ:VIGLVigil Neuroscience Inc
13/03/202412h05GlobeNewswire Inc.Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual MeetingNASDAQ:VIGLVigil Neuroscience Inc
12/03/202412h05GlobeNewswire Inc.Vigil Neuroscience to Present at Stifel 2024 Virtual CNS DaysNASDAQ:VIGLVigil Neuroscience Inc
06/03/202422h25GlobeNewswire Inc.Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024NASDAQ:VIGLVigil Neuroscience Inc
02/03/202400h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
01/03/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIGLVigil Neuroscience Inc
29/02/202422h05GlobeNewswire Inc.Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024NASDAQ:VIGLVigil Neuroscience Inc
14/02/202417h33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VIGLVigil Neuroscience Inc
07/02/202422h05GlobeNewswire Inc.Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:VIGLVigil Neuroscience Inc
11/01/202416h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
03/01/202422h30GlobeNewswire Inc.Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 MilestonesNASDAQ:VIGLVigil Neuroscience Inc
22/11/202322h05GlobeNewswire Inc.Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:VIGLVigil Neuroscience Inc
16/11/202322h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
16/11/202322h05GlobeNewswire Inc.Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATENASDAQ:VIGLVigil Neuroscience Inc
07/11/202313h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIGLVigil Neuroscience Inc
07/11/202313h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
07/11/202313h05GlobeNewswire Inc.Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIGLVigil Neuroscience Inc
17/10/202313h05GlobeNewswire Inc.Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s DiseaseNASDAQ:VIGLVigil Neuroscience Inc
12/10/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIGLVigil Neuroscience Inc
05/10/202322h01GlobeNewswire Inc.Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro SummitNASDAQ:VIGLVigil Neuroscience Inc
 Showing the most relevant articles for your search:NASDAQ:VIGL

Kürzlich von Ihnen besucht

COIN
VTMUSD
Victorieum
TIDE
ETHGBP
Ethereum
LSE
04LC
Citibk.citi.uts
EU
U1FA
UBS Lux Fund Solutions M...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten